Immunodeficiency Virus (e.g., Hiv, Etc.) Patents (Class 424/208.1)
  • Patent number: 10279027
    Abstract: The present relation relates to a transgenic Vero cell line expressing CD4 and CCR5. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 7, 2019
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Wayne C. Koff
  • Patent number: 10220087
    Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 5, 2019
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
  • Patent number: 10039823
    Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 ?g of a lipopolysaccharide and between 1 and 30 ?g of an immunologically active saponin fraction presented in the form of a liposome.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: August 7, 2018
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventor: Pierre Vandepapeliere
  • Patent number: 10017542
    Abstract: Aspects of the present invention relate to peptides having antimicrobial activity. In certain aspects, the invention relates to peptides having potent antimicrobial activity, broad-spectrum antimicrobial activity, and/or the ability to kill otherwise antibiotic-resistant microbes, or microbes protected by biofilms.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: July 10, 2018
    Assignee: Riptide Bioscience, Inc.
    Inventors: Jesse Jaynes, L. Edward Clemens, Henry W. Lopez, George R. Martin, Kathryn Woodburn
  • Patent number: 9957300
    Abstract: Briefly described, virus-like particles, methods of preparing virus-like particles, immunogenic compositions that include virus-like particles, and methods of eliciting an immune response using immunogenic compositions that include virus-like particles are described herein. A virus-like particle (VLP) can include a viral core protein that can self assemble into the VLP core and at least one viral surface envelope glycoprotein expressed on the surface of the VLP. The VLP can also optionally include at least one adjuvant molecule expressed on the surface of the VLP.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: May 1, 2018
    Assignee: Emory University
    Inventors: Richard W. Compans, Chinglai Yang, Qizhi Yao, Sang-moo Kang
  • Patent number: 9925258
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: March 27, 2018
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Wayne C. Koff
  • Patent number: 9920347
    Abstract: Methods for producing virus particles and viral antigens with simplified glycosylation profiles, such as mono-glycosylated forms of HIV, HCV, Dengue virus, West Nile virus and influenza virus. When used as targets for vaccine production, the conserved nature of such sites generate vaccines that are less sensitive to viral mutations. Such methods may include the use of glycosylation inhibitors for production of viruses or viral antigens with simplified glycosylation profiles.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 20, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Che Ma, Yung-Chieh Tseng
  • Patent number: 9750687
    Abstract: Provided is a method for easily and efficiently producing encapsulated substance vesicles wherein a substance is encapsulated in the cavity of vesicles obtained by polymer self-assembly. Empty vesicles that have membranes comprising a first polymer that is a block copolymer with uncharged hydrophilic segments and a first kind of charged segments and a second polymer with a second kind of charged segments that carry a charge that is the opposite of said first kind of charged segments as well as spaces that are enclosed by said membranes are mixed in an aqueous medium with the substance that is to be encapsulated in the spaces.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: September 5, 2017
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Kazunori Kataoka, Akihiro Kishimura, Yasutaka Anraku, Kanjiro Miyata, Sayan Chuanoi, Tomoya Suma, Makoto Oba
  • Patent number: 9687480
    Abstract: Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion. The present invention provides chiral (2S)-1-(4-methylphenylmethyl)-5-oxo-(3S)-{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)-{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p-methylphenylmethyl)1pyroglutamate in good chiral purity.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: June 27, 2017
    Assignee: Council of Scientific & Industrial Research
    Inventors: Dinesh Kumar Dikshit, Madhu Dikshit, Tanveer Irshad Siddiqui, Anil Kumar, Rabi Sankar Bhatta, Girish Kumar Jain, Manoj Kumar Barthwal, Ankita Misra, Vivek Khanna, Prem Prakash, Manish Jain, Vishal Singh, Varsha Gupta, Anil Kumar Dwivedi
  • Patent number: 9644188
    Abstract: Certain embodiments of the invention relate to mutant forms of flock house virus B2 protein characterized by having enhanced suppressor of RNA silencing activity as compared to wild type flock house virus B2 protein. Certain embodiments of the invention relate to nucleic acid sequences and vectors that encode and/or direct expression of such mutant forms of flock house virus B2 protein in eukaryotic cells. Certain embodiments of the invention relate to methods of using such mutant forms of flock house virus B2 protein and/or nucleic acid sequences and vectors that encode and/or direct expression thereof in eukaryotic cells to increase a replication rate of a plant or animal virus in a plant or animal cell.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 9, 2017
    Inventors: Aln Rao, Jang-Kyung Seo
  • Patent number: 9376484
    Abstract: The present invention provides cell lines deficient in mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase I (Mgat1). Also provided are methods for producing the Mga1 deficient cell lines and methods for using the Mgat1 deficient cell lines for the production of recombinant proteins having simple glycoforms.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: June 28, 2016
    Assignee: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Natalie Sealover, Henry George, Kevin Kayser
  • Patent number: 9296790
    Abstract: The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: March 29, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Deb Chatterjee, Stanislaw Jan Kaczmarcyk
  • Patent number: 9259433
    Abstract: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: February 16, 2016
    Assignee: The Johns Hopkins University
    Inventors: Ru Chih C. Huang, Ibrahim S. Abd-Elazem
  • Patent number: 9206155
    Abstract: Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion The present invention provides chiral (2S)-1-(4-methyl-phenylmethyl)-5-oxo-(3S)—{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)—{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p methylphenylmethyl)lpyroglutamate in good chiral purity.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: December 8, 2015
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Dinesh Kumar Dikshit, Madhu Dikshit, Tanveer Irshad Siddiqui, Anil Kumar, Rabi Sankar Bhatta, Girish Kumar Jain, Manoj Kumar Barthwal, Ankita Misra, Vivek Khanna, Prem Prakash, Manish Jain, Vishal Singh, Varsha Gupta, Anil Kumar Dwivedi
  • Patent number: 9119811
    Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: September 1, 2015
    Assignee: Vaxin UK Limited
    Inventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
  • Patent number: 9115186
    Abstract: Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: August 25, 2015
    Assignee: New York Blood Center
    Inventors: Shibo Jiang, Zhi Qi, Xi Chen, Chungen Pan
  • Patent number: 9101578
    Abstract: Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: August 11, 2015
    Assignee: TechnoVax, Inc.
    Inventors: Jose M. Galarza, Demetrius Matassov
  • Publication number: 20150147355
    Abstract: The present invention relates to a vaccination strategy that establishes protective immunity, including a protective memory T-cell population.
    Type: Application
    Filed: March 8, 2013
    Publication date: May 28, 2015
    Inventors: Akiko Iwasaki, Norifuma Iijima, Haina Shin
  • Publication number: 20150140068
    Abstract: This invention generally relates to immunogenic compositions that comprise an HIV RNA component and a HIV polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from human immunodeficiency virus (HIV), in RNA-coded form; and a second epitope from HIV, in polypeptide form—are effective in inducing immune response to HIV. The invention also relates to a kit comprising an HIV RNA-based priming composition and an HIV polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.
    Type: Application
    Filed: June 29, 2013
    Publication date: May 21, 2015
    Inventors: Susan Barnett, Kaustuv Bannerjee, Gillis Otten, Andrew Geall
  • Publication number: 20150125489
    Abstract: The present invention relates to a process for obtaining an antigen-loaded dendritic cell showing higher viability and migratory capacity towards lymphatic nodes. The invention also relates to vaccines containing said dendritic cells as well as to the use thereof for the treatment of infectious diseases, especially AIDS.
    Type: Application
    Filed: March 1, 2013
    Publication date: May 7, 2015
    Inventors: Felipe García Alcaide, Teresa Gallart, Nùria Climent Vidal, Cristina Gil Roda, Josep María Gatell Artigas
  • Patent number: 9023648
    Abstract: The invention is directed to a chimeric gammaretrovirus comprising an gammaretroviral virion which contains a lentiviral Vpx protein and methods of use thereof. In a particular aspect, the chimeric gammaretrovirus is a chimeric murine leukemia virus (MLV) comprising an MLV virion which contains a lentiviral Vpx protein. The invention is also directed to use of the chimeric gammaretrovirus to produce a MLV that can transduce a non-dividing cell (G1/S/G2), transduce a non-dividing cell; enhance the ability of a MLV to transduce a non-dividing cell; transduce a quiescent (G0) cell; and enhance the ability of a human immunodeficiency virus 1 (HIV-1) to transduce a quiescent (G0) cell.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: May 5, 2015
    Assignee: University of Massachusetts
    Inventors: Mario Stevenson, Rajnish Kaushik, Xiaonan Zhu
  • Patent number: 9017935
    Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: April 28, 2015
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie Pacchia
  • Patent number: 9017699
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 28, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Publication number: 20150110836
    Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.
    Type: Application
    Filed: May 21, 2013
    Publication date: April 23, 2015
    Inventor: Jacob E. Glanville
  • Patent number: 9011873
    Abstract: The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Duke University, Beth Israel Deaconess Medical Center, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, William Fischer, Hua-Xin Liao, Barton F. Haynes, Norman Letvin, Beatrice H. Hahn
  • Patent number: 9011875
    Abstract: The present invention relates to mosaic HIV-1 group M Gag sequences and to a composition comprising same.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Beth Israel Deaconess Medical Center, Duke University, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, Simon Perkins, Tanmoy Bhattacharya, William M. Fischer, James Theiler, Norman Letvin, Barton F. Haynes, Beatrice H. Hahn, Karina Yusim, Carla Kuiken
  • Patent number: 9005889
    Abstract: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: April 14, 2015
    Assignee: The Johns Hopkins University
    Inventors: Ru Chih C. Huang, Ibrahim S. Abd-Elazem
  • Patent number: 8999350
    Abstract: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: April 7, 2015
    Assignee: Universite d'Aix-Marseille
    Inventor: Erwann Loret
  • Patent number: 8980546
    Abstract: This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: March 17, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 8980610
    Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: March 17, 2015
    Assignee: Biogen Idec MA Inc.
    Inventors: Keith Selvitelli, Justin McCue
  • Publication number: 20150072016
    Abstract: Microparticles with adsorbed polynucleotide-containing species, compositions containing the same, methods of making such microparticles, and uses thereof are disclosed. The microparticles comprise (a) a biodegradable polymer, such as a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, or a polycyanoacrylate, (b) a cationic surfactant such as cetyltrimethylammonium bromide, (c) and a polynucleotide-containing species adsorbed on the surface of the microparticles, wherein the polynucleotide-containing species constitutes at least 5 percent of the total weight of said microparticles. Examples of polynucleotide-containing species include polynucleotide-containing immunological adjuvants, such as CpG oligonucleotides, and polynucleotide-containing species that encode polypeptide-containing antigens, such as RNA and DNA vector constructs.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Inventors: Derek O'HAGAN, Manmohan SINGH
  • Publication number: 20150056246
    Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: David A. Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
  • Publication number: 20150050309
    Abstract: The present invention relates, in-general, to Human immunodeficiency virus (HIV), and in particular to a carbohydrate-based vaccine for HIV and to methods of making and using same.
    Type: Application
    Filed: July 16, 2014
    Publication date: February 19, 2015
    Applicants: Duke University, University of Kansas
    Inventors: Barton F. HAYNES, Heather Desaire, Eden P. Go
  • Publication number: 20150050307
    Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.
    Type: Application
    Filed: March 29, 2013
    Publication date: February 19, 2015
    Inventors: Christopher James Nicolai, Semih U. Tareen
  • Patent number: 8956627
    Abstract: The present invention relates to a method of inducing the production in a patient of anti-HIV antibodies. The method comprises administering to a patient in need thereof an amount of at least one liposome-peptide conjugate in an amount sufficient to effect that induction. The peptide comprises a membrane external proximal region (MPER) epitope and the liposome comprises lysophosphorylcholine or phosphatidylserine.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: February 17, 2015
    Assignee: Duke University
    Inventors: Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
  • Publication number: 20150037371
    Abstract: The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite). The invention also features vaccines, expression vectors, and methods for the manufacture and use thereof.
    Type: Application
    Filed: October 14, 2014
    Publication date: February 5, 2015
    Inventor: Samuel J. LANDRY
  • Patent number: 8936789
    Abstract: Provided herein are immunogenic compositions comprising fusion proteins, the fusion proteins comprising lentivirus gp41 or a fragment thereof, a trimerization or oligomerization motif and an immunoenhancer that elicit potent and broad HIV neutralizing antibody responses in the immunized hosts. Also disclosed are methods of making and using the immunogenic compositions.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: January 20, 2015
    Assignee: New York Bood Center, Inc.
    Inventors: Shibo Jiang, Zhi Qi, Chungen Pan
  • Patent number: 8932603
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: January 13, 2015
    Assignee: Vaccibody AS
    Inventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
  • Patent number: 8932599
    Abstract: The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: January 13, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Paris Est Creteil Val de Marne
    Inventors: Yves Levy, Jean-Marc Balloul, Doris Schmitt, Caterina Riconda Guillet
  • Publication number: 20150010594
    Abstract: A method for inducing an immune response against HIV in a subject includes preparing first and second HIV-1 protein coding sequences, introducing the first and second HIV-1 protein coding sequence into first and second expression constructs using yeast homologous recombination, transfecting a cell with the first and second, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Inventor: Yong Gao
  • Patent number: 8926995
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: January 6, 2015
    Assignee: Duke University
    Inventors: Barton F. Haynes, Laurent Verkoczy, M. Anthony Moody, Matt T. Holl, Masayuki Kuraoka, Garnett Kelsoe
  • Publication number: 20150004132
    Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).
    Type: Application
    Filed: December 20, 2013
    Publication date: January 1, 2015
    Applicants: EMORY UNIVERSITY, Centers for Disease Control and Prevention, The United States of America as Represented by the Department of Health and Human Services
    Inventors: Harriet Robinson, James Smith, Ram Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
  • Publication number: 20140377307
    Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.
    Type: Application
    Filed: October 8, 2013
    Publication date: December 25, 2014
    Applicant: GEORGIA REGENTS RESEARCH INSTITUTE, INC.
    Inventors: DAVID MUNN, ANDREW MELLOR
  • Patent number: 8916174
    Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: December 23, 2014
    Assignees: National Institute for Agricultural Research, University of Kansas Medical Center
    Inventors: Yahia Chebloune, Euan Narayan
  • Publication number: 20140370052
    Abstract: The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
    Type: Application
    Filed: December 17, 2012
    Publication date: December 18, 2014
    Inventors: Nuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado
  • Patent number: 8911728
    Abstract: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: December 16, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen
  • Publication number: 20140341949
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Application
    Filed: October 3, 2012
    Publication date: November 20, 2014
    Applicants: DUKE UNIVERSITY, Children's Medical Center Corporation
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • Publication number: 20140335126
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.
    Type: Application
    Filed: December 5, 2012
    Publication date: November 13, 2014
    Inventors: Barton F. Haynes, Huaxin Liao, Jerome Kim, Nelson Michael, Susan B. Zolla-Pazner
  • Publication number: 20140335074
    Abstract: Methods are provided herein for enhancing the effectiveness of medical therapies by administering agents that suppress a biological damage response that is inducible by the medical therapy administered to a subject. In certain embodiments, a method is provided for administering an anti-senescent cell agent that suppresses a biological response comprising cellular senescence that is induced by the medical therapy.
    Type: Application
    Filed: December 13, 2012
    Publication date: November 13, 2014
    Inventors: Judith Campisi, Marco Demaria
  • Patent number: 8883745
    Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: November 11, 2014
    Assignees: New York University, The Aaron Diamond Aids Research Center For The City Of New York, Research Foundation Of The City University Of New York
    Inventors: Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang